Amblyotech Email Format
Biotechnology Research2-10 Employees
Amblyotech is a small biotechnology research company based in Phoenix, Arizona, that develops electronic media therapies for amblyopia and other ocular conditions in both children and adults. Its products are digital treatments designed to be used by patients to deliver therapy through interactive media, including game-based approaches intended to stimulate visual processing in each eye. The work sits at the intersection of vision science and digital therapeutics, seeking non-invasive options to improve binocular vision. The company's target market comprises patients with amblyopia and related ocular conditions who may benefit from non-invasive digital therapies. A notable development occurred in April 2020 when Novartis Pharmaceuticals Corporation acquired Amblyotech. Previously, in 2018, Amblyotech released Dig Rush, a game-based therapeutic concept developed with Ubisoft for children with amblyopia.